Carbon To Carbon Unsaturation In R Patents (Class 514/627)
  • Publication number: 20110236460
    Abstract: Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate.
    Type: Application
    Filed: March 18, 2011
    Publication date: September 29, 2011
    Inventors: Joshua Stopek, Amin Elachchabi, Daniel Broom, Garrett Ebersole
  • Publication number: 20110196042
    Abstract: The invention provides (1) genes differentially expressed in animals administered fatty acid amides that affect one or more of food intake, satiety, lipid metabolism, and fat utilization and (2) compositions and methods relating to the use of the genes to identify new compounds that affect one or more of food intake, satiety, lipid metabolism, and fat utilization.
    Type: Application
    Filed: August 10, 2009
    Publication date: August 11, 2011
    Inventors: Delphine Tissot-Favre, Frederic Destaillats, Clementine Thabuis, Jean-Charles Martin
  • Publication number: 20110196043
    Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.
    Type: Application
    Filed: April 8, 2011
    Publication date: August 11, 2011
    Applicant: NeurogesX, Inc.
    Inventors: Naweed Muhammad, Gene C. Jamieson, Keith R. Bley, Sanjay Chanda
  • Publication number: 20110189270
    Abstract: A medical device includes a substrate having at least one surface. The surface has a central portion and a peripheral portion. At least one bioactive agent is disposed over at least a portion of the surface. The medical device having a concentration gradient of the at least one bioactive between the central and peripheral portions.
    Type: Application
    Filed: January 10, 2011
    Publication date: August 4, 2011
    Applicant: Tyco Healthcare Group LP
    Inventors: Daniel Broom, Joshua Stopek, Amin Elachchabi
  • Publication number: 20110182972
    Abstract: Described here are patches and methods for treating neuropathic pain. In some variations, the neuropathic pain-relieving patch comprises capsaicin or a capsaicin analog, wherein the concentration of the capsaicin or capsaicin analog is less than 1% by weight, and a penetration enhancer, wherein the patch is capable of relieving neuropathic pain over a sustained period of time. The penetration enhancer may be any suitable penetration enhancer. The patches may also include oils, viscosity increasing agents, and the like. In some variations, the pain-relieving patches comprise capsaicin, or an, wherein the concentration of the capsaicin or analog is less than 1%, and a penetration enhancer, whereby delivery of capsaicin from the patch continues for at least an hour, and whereby a single use of the patch provides a therapeutic benefit for at least one month, two months, or three months. Methods for treating neuropathic pain are also described.
    Type: Application
    Filed: April 8, 2011
    Publication date: July 28, 2011
    Applicant: NeurogesX, Inc.
    Inventor: Keith R. Bley
  • Publication number: 20110184069
    Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.
    Type: Application
    Filed: April 8, 2011
    Publication date: July 28, 2011
    Applicant: NeurogesX, Inc.
    Inventors: Naweed MUHAMMAD, Gene C. Jamieson, Keith R. Bley, Sanjay Chanda
  • Publication number: 20110178151
    Abstract: The present invention relates to novel fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as agents for the treatment of obesity and related disorders, and for improving cognition.
    Type: Application
    Filed: March 4, 2009
    Publication date: July 21, 2011
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
    Inventors: Jehoshua Katzhendler, Elliot Berry, Yosefa Avraham, Yousef Najajreh, Meir Saidian, Raphael Mevorach
  • Publication number: 20110172305
    Abstract: The present invention relates to a method for promoting infant feeding, growth or development comprising administering to an infant a formula or a pharmaceutical composition comprising an endocannabinoid in an amount sufficient to promote feeding, growth or development. The present invention also relates to an infant formula comprising an enhanced amount of an endocannabinoid. The infant formula of the invention may be in a powder form or in a liquid form. The infant formula or the pharmaceutical composition may further comprise an endocannabinoid-promoting compound.
    Type: Application
    Filed: October 2, 2008
    Publication date: July 14, 2011
    Inventors: Ester Fride, Ayala Polak-moshe, David Branski, Shimon Ben-Shabat
  • Patent number: 7976880
    Abstract: Pregnane glycoside or a Caralluma extract including the pregnane glycoside of the present invention can be used for medical purposes and as food additives, such as a treatment of obesity, a reduction of blood glucose, a reduction of blood pressure, a reduction in hip, waist and arm circumferences, a reduction of fat, increase of BMR, a decrease of BMI, an increase of lean body mass, an appetite-suppression and a reduction/elimination of joint pain, anti-aging, a treatment for falling sex drive, the treatment for impotency and an erectile dysfunction, and an enhancement of energy levels.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: July 12, 2011
    Inventors: Ramaswamy Rajendran, Kamala Rajendran
  • Publication number: 20110166196
    Abstract: Provided are methods for treatment and prophylaxis of convulsive disorders and seizures, such as epilepsy and febrile seizures, by modulating TRPV1 channel activation.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 7, 2011
    Inventors: Julie A. Kauer, Barry W. Connors, Jennifer A. Kim, Helen E. Gibson
  • Publication number: 20110165198
    Abstract: The invention provides methods for using fatty acid alkanolamides for reducing lipid absorption from the intestine of an animal. Reducing lipid absorption results in fewer lipids available for an animal to convert to body fat. Converting fewer lipids to body fat means that the animal reduces body fat, body weight, and/or body weight gain when consuming an equivalent amount of lipids without the fatty acid alkanolamides.
    Type: Application
    Filed: May 15, 2009
    Publication date: July 7, 2011
    Inventors: Delphine Tissot-Favre, Frederic Destaillats, Yuanlong Pan, Fabiola Dionisi, Cristina Cruz-Hernandez, Clementine Thabuis, Jean-Charles Martin
  • Publication number: 20110135627
    Abstract: A composition for the relief of pain includes comprising a transducer, a fibrinolytic, at least one of a pain relief agent or an anti-inflammatory agent. The pain relief agent can be capsaicin and the fibrinolytic can be bromelain. The composition can also include at least one of a cooling component, a circulation increasing component, a joint or muscle soothing component and a muscle membrane stabilizer. the cooling agent fcan be menthol. A cream composition can include at least one cetyl esterified fatty acid. A cream can be made by combining the oil with a cream base. Suitable compositions include creams, gels, salves, sprays, powder, balms, liniment, ointments, and transdermal patches A system for pain relief that includes the oil and the cream, or a kit containing a container of the oil and a container of the cream.
    Type: Application
    Filed: October 7, 2010
    Publication date: June 9, 2011
    Applicant: The Inflasoothe Group, Inc.
    Inventors: Richard LaMotta, Robert Ornstein, Douglas Redfield, Vijay Vad
  • Publication number: 20110118347
    Abstract: A compound of the formula CH3(CH2)n—RA—(CH2)m-(CH?CH)q—(CH2)p—X wherein RA=(a); q=0 or 1; m and p are independently selected integers of at least 1; n=0 or an integer of at least 1; X is a polar group selected from —CO2RS, where Rs?H, Na, K, —NHRI, —NRIRII or RIII; —CH3OH; —CH3NH2; —CH3NHRI; or —CH3NRIRII; wherein RI, RII and RIII are independently selected from C1-C6 alkyl or an aryl group, preferably a hydrophilically substituted C1-C6 alkyl or aryl group, or RIII is an esterified glycol; and wherein 20>m+n+p+2q?2; is useful for the treatment of ringworm infection caused by Trichophyton tonsurans.
    Type: Application
    Filed: May 29, 2009
    Publication date: May 19, 2011
    Applicant: Vernolix Limited
    Inventor: Michael William Fowler
  • Publication number: 20110086818
    Abstract: The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non-pain-sensing neurons or other types of cells.
    Type: Application
    Filed: March 11, 2009
    Publication date: April 14, 2011
    Applicants: Presidents and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Bruce P. Bean, Clifford J. Woolf
  • Publication number: 20110077239
    Abstract: A medicament for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the production of such a medicament, and a method for the treatment of such phantom phenomena
    Type: Application
    Filed: June 18, 2010
    Publication date: March 31, 2011
    Inventors: Marlies Knipper, Lukas Ruettiger, Bernhard Schick, Julia Dlugaiczyk
  • Publication number: 20110065801
    Abstract: The invention relates to the enzymatic synthesis of sphingolipids and compositions comprising sphingolipids from lysosphingolipids and carboxylic esters, and to cosmetic, dermatological or pharmaceutical formulations which comprise these sphingolipids or compositions.
    Type: Application
    Filed: May 22, 2009
    Publication date: March 17, 2011
    Applicant: EVONIK GOLDSCHMIDT GMBH
    Inventors: Frank Hollmann, Oliver Thum, Pawel Grzebyk, Christoph Toelle
  • Publication number: 20110065627
    Abstract: This invention describes a topical delivery mechanism that contains a mixture of cetylated fatty esters that act as transdermal carriers of desired therapeutic molecules. The proposed cetyl fatty ester penetrant-complex (Base CFEP-complex) contains specific cetyl fatty esters, polar solvents, a carrier base (gel, cream, lotion, patch or stick gel), antioxidants and the desired pharmaceutical, cosmetic or antigenic response eliciting molecules that are efficaciously delivered by selectively varying component ratios in the complex.
    Type: Application
    Filed: October 29, 2009
    Publication date: March 17, 2011
    Applicant: CYMBIOTICS INC.
    Inventors: Raj R. Barathur, Jack Bain Bookout
  • Publication number: 20110059177
    Abstract: The invention relates to improved cardioplegia solutions. The invention provides cardioplegia solutions and compositions that produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The cardioplegia solutions and compositions are used for arresting, protecting and/or preserving organs, in particular the heart during open-heart surgery, transplanting, cardiovascular diagnosis or therapeutic intervention.
    Type: Application
    Filed: February 10, 2009
    Publication date: March 10, 2011
    Inventor: Hemant Thatte
  • Publication number: 20110045073
    Abstract: The present invention relates to controlled release composition for preventing and/or treating microbial infections in the oral cavity of a subject, said composition comprising a controlled delivery matrix which matrix has releasably associated therewith an amount of between 0.000009 and 5 wt % of a sphingolipid, wherein the composition provides a sphingolipid-release-profile in the oral cavity of a subject, wherein said release-profile is maintained for between 15 seconds and 24 hours and wherein said release-profile provides for a concentration of said sphingolipid in the saliva of said subject of between 20 ?mole/L and 250 ?mole/L.
    Type: Application
    Filed: February 19, 2009
    Publication date: February 24, 2011
    Applicant: INNOPACT B.V.
    Inventor: Peter Frank Ekhart
  • Patent number: 7888393
    Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-C30 fatty alcohol, monoglyceride or the reaction products thereof.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: February 15, 2011
    Assignee: Microdermis Corporation
    Inventor: Griscom Bettle, III
  • Publication number: 20110033525
    Abstract: Several diterpene glycosides (e.g., rubusoside, rebaudioside, steviol monoside and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, and celecoxib. The use of the diterpene glycoside rubusoside increased solubility in all tested compounds. The diterpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries. Aqueous solutions by using rubusoside to increase the solubility of otherwise insoluble drugs will have several new routes of administration. In addition, aqueous solutions of therapeutic compounds with rubusoside were shown to retain the known pharmacological activity of the compounds.
    Type: Application
    Filed: April 13, 2009
    Publication date: February 10, 2011
    Inventor: Zhijun Liu
  • Publication number: 20110033503
    Abstract: Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed.
    Type: Application
    Filed: April 23, 2008
    Publication date: February 10, 2011
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Stanley Stein, Anupa R. Menjoge, Simi Gunaseelan, Siva Naga Sree priay Anumolu, Raghavandra Navath
  • Publication number: 20110028382
    Abstract: The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex.
    Type: Application
    Filed: October 7, 2008
    Publication date: February 3, 2011
    Inventor: Kevin Burke Miller
  • Publication number: 20110027326
    Abstract: An external composition for skin is provided, which gives good warmth without inducing irritation or pain and whose sustainability of warmth is good. The external composition for skin contains (A) an agent for giving warmth and (B) at least one member selected from the group consisting of fatty acid esters of aliphatic polyhydric alcohols and aromatic carboxylic acid esters of lower alcohols or aliphatic polyhydric alcohols.
    Type: Application
    Filed: March 26, 2009
    Publication date: February 3, 2011
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiyuki Hirayama
  • Publication number: 20110014269
    Abstract: A dermal method of treating chronic post-operative pain with a TRPV-1 receptor modulator. More specifically, a method for treating localized post-incisional neuropathic pain by administering a civamide-containing patch.
    Type: Application
    Filed: July 9, 2010
    Publication date: January 20, 2011
    Applicant: WINSTON LABORATORIES, INC.
    Inventor: Joel E. Bernstein
  • Publication number: 20100330187
    Abstract: The invention relates to a food additive that includes, relative to the total weight thereof: about 3.5 wt % of capsicum oleoresin containing 6 wt % of a capsaicine and dihydrocapsaicine mixture; about 5.5 wt % of cinnamaldehyde; about 9.5 wt % of eugenol; the balance up to 100% consisting of hydrogenated vegetable oils. The invention also relates to the uses of said additive for improving the daily distribution of food ingestion by animals, for increasing the amount of water drunk by animals, or for preparing a food product intended for the preventive or therapeutic treatment of animal digestive disorders, such as acidosis or bloating. This food additive is particularly adapted for ruminants such as bovine cattle.
    Type: Application
    Filed: January 16, 2009
    Publication date: December 30, 2010
    Applicant: PANCOSMA SOCIETE ANONYME POUR L'INDUSTRIE DES PRODUITS BIOCHIMIQUES
    Inventors: David Bravo, Sergio Calsamiglia
  • Publication number: 20100322961
    Abstract: The present invention provides an intranasal drug delivery system containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin in the form of oleoresin capsicum used as a carrier to quickly and effectively deliver a drug.
    Type: Application
    Filed: August 3, 2010
    Publication date: December 23, 2010
    Inventor: Wayne Jeffrey Perry
  • Publication number: 20100316742
    Abstract: A solution and method for treating symptoms commonly associated with fibromyalgia. The solution includes a solvent and a composition including active ingredients of menthol, camphor, and capsaicin, as well as additional components including aloe vera extract, carbomer, decyl polyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose water, silica, sodium, hydroxymethyl glycinate, vegetable glycerin, witch hazel, and yucca extract. The method includes soaking an affected area in the solution for a predetermined period of time.
    Type: Application
    Filed: June 15, 2009
    Publication date: December 16, 2010
    Inventor: Joe D. Kingsley
  • Publication number: 20100316678
    Abstract: The present invention relates generally to the field of pain management, and in particular, the management of neuropathic pain. The present invention further provides methods and compositions that treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic pain without inducing overt sedation. The present invention also contemplates combination therapy using one or more NK antagonists in combination with one or more compounds which decrease or inhibit neuronal excitation in the treatment of pain in association with the treatment of a particular disease condition or pathology.
    Type: Application
    Filed: June 26, 2008
    Publication date: December 16, 2010
    Applicant: CNSBio Pty Ltd.
    Inventor: Colin Stanley Goodchild
  • Publication number: 20100303932
    Abstract: The present invention is a method for attenuating the effects of botulinum toxin poisoning using capsaicin and/or a capsaicin analog.
    Type: Application
    Filed: May 27, 2010
    Publication date: December 2, 2010
    Inventors: Baskaran Thyagarajan, Joseph J. McArdle
  • Publication number: 20100291005
    Abstract: The invention concerns the use of 2E,4E-decadienoic acid-N-isobutylamide (trans-pellitorin) as flavorant, in particular as salivation inducing flavor substance, preferably in a foodstuff or nutrient, an oral hygienic preparation or a gourmet or snack preparation. Further, the invention concerns preparations, semi-finished preparations as well as fragrance, aroma and taste compositions, containing trans-pelletorin as well as a processes for the production of trans-pelletorin.
    Type: Application
    Filed: July 6, 2010
    Publication date: November 18, 2010
    Applicant: Symrise GmbH & Co. KG
    Inventors: Ian Lucas Gatfield, Jakob Peter Ley, Gerhard Krammer, Heinz-Juergen Bertram, Ilse Loenneker, Arnold Machinek
  • Publication number: 20100290998
    Abstract: Methods of inhibiting ischemia-related and ischemia-reperfusion-related injury are provided. Remote administration of a C-fiber activator or TRPV1 agonist or remote electrical stimulation and activation of TRPV1 reduces ischemia-related tissue damage in subjects at risk for ischemia-related tissue damage. In aspects of the invention, remote application of a TRPV1 agonist inhibits ischemia-related cardiac tissue damage. Methods of inhibiting cardiac tissue damage by topically administering the TRPV1 agonist, capsaicin are provided.
    Type: Application
    Filed: May 7, 2010
    Publication date: November 18, 2010
    Inventors: W. Keith Jones, Xiaoping Ren, Neal Lee Weintraub
  • Publication number: 20100273887
    Abstract: The present invention relates to products and mixtures comprising (a) pellitorin and (b) selected cooling agents. The present invention further relates to products and medicaments for soothing irritated oral and/or nasal tissues. The present invention also relates to the use of such mixtures for soothing irritated oral and/or nasal tissues and the use of such mixtures for reducing bitterness, in particular the bitterness of oral care products, confectionery products and medicaments, more specifically reducing the bitterness of menthol and menthol containing products and medicaments.
    Type: Application
    Filed: August 16, 2007
    Publication date: October 28, 2010
    Applicant: SYMRISE GMBH & CO. KG
    Inventors: Arnold Machinek, Ingo Wöhrle, Jakob Peter Ley, Günter Kindel
  • Publication number: 20100267670
    Abstract: The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
    Type: Application
    Filed: July 6, 2010
    Publication date: October 21, 2010
    Inventors: Xuqing Zhang, Xiaojie Li, Zhihua Sui
  • Publication number: 20100234379
    Abstract: The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor. Disruption of such signals has been shown to prevent neuronal maintenance processes and increase vulnerability to brain damage. Here, blocking endocannabinoid inactivation enhanced cannabinergic activity and ameliorated cellular disturbances associated with excitotoxicity. Modulating the endocannabinoid system in this way also prevented excitotoxic behavioral abnormalities including memory impairment. Collectively, these results indicate that increasing endocannabinoid responses by inhibiting the endocannabinoid transported and/or the inhibiting FAAH leads to molecular, cellular, and functional protection against excitotoxic insults like stroke and traumatic brain injury.
    Type: Application
    Filed: July 28, 2006
    Publication date: September 16, 2010
    Inventors: Ben A. Bahr, Alexandros Makriyannis, David A. Karanian
  • Publication number: 20100234470
    Abstract: This present invention relates to methods for treating or attenuating pain in a patient. Specifically, the invention provides a method for attenuating pain in proximity to the site of an open wound or surgical incision comprising instilling a pharmaceutical composition comprising a capsaicinoid into the wound or incision, allowing the pharmaceutical composition to dwell for a predetermined period of time, and aspirating the wound or incision to remove the pharmaceutical composition. The invention also provides a method for attenuating pain in proximity to a joint comprising intra-articularly injecting a pharmaceutical composition comprising a capsaicinoid into the joint, allowing the pharmaceutical composition to dwell for predetermined period of time, and aspirating the joint to remove the pharmaceutical composition. In certain embodiments of the invention, the capsaicinoid is capsaicin.
    Type: Application
    Filed: September 14, 2009
    Publication date: September 16, 2010
    Applicant: ANESIVA, INC.
    Inventors: Lakshmi Sangameswaran, Susan Kramer
  • Publication number: 20100234454
    Abstract: The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.
    Type: Application
    Filed: June 11, 2007
    Publication date: September 16, 2010
    Applicants: Katholieke Universiteit Leuven K.U. Leuven R&D, University of Hawaii
    Inventors: Eva Cuypers, Evert Karlsson, Jan Tytgat, Angel Yanagihara
  • Publication number: 20100204313
    Abstract: The present invention is directed to the treatment of chronic pain that occurs in chronic disease such as chronic pancreatitis by the application, of the drug, resiniferatoxin, to a visceral organ, such as the stomach, which then reduces the pain present in a second visceral organ, such as the pancreas. The reduction of said pain associated with the chronic disease occurs through the drug-induced desensitization of primary pain-sensing neurons that are shared between the two visceral organs. Additionally, application of the drug resiniferatoxin into the first organ, reduces the inflammation that occurs in the second diseased organ. This modulation of shared nerve activity by application of resiniferatoxin, may also be directed to modulate the pain and inflammation in any two visceral organs that share a common spinal or vagal nerve. Finally, application of the drug resiniferatoxin to either the stomach or the jejunum may be used to treat disease and disorders that involve gastroparesis.
    Type: Application
    Filed: April 16, 2010
    Publication date: August 12, 2010
    Inventor: Pankaj J. Pasricha
  • Publication number: 20100197795
    Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-C30 fatty alcohol, monoglyceride or the reaction products thereof.
    Type: Application
    Filed: April 13, 2010
    Publication date: August 5, 2010
    Applicant: Drs. Solutions, LLC
    Inventors: Griscom Bettle, III, William S. Coury
  • Publication number: 20100190860
    Abstract: This document features methods related to selectively inducing nociceptor blockade. For example, methods of treating pain by administering antinociceptor agents are provided.
    Type: Application
    Filed: January 8, 2010
    Publication date: July 29, 2010
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Peter Gerner, Ging Kou Wang
  • Publication number: 20100184863
    Abstract: The present application provides a synthetic spilanthol flavor composition that includes (2E,6Z,8E)-N-(2-methylpropyl)-2,6,8-decatrienamide. The synthetic spilanthol composition can also contain, and at least one of (2E, 6E, 8E)-N-(2-methylpropyl)-2,6,8-decatrienamide and (2E, 6Z, 8Z)-N-(2-methylpropyl)-2,6,8-decatrienamide, the (N-(2-methylpropyl)-2,6,8-decatrienamide being present in amounts effective to impart a salivating or tingle effect while reducing the perception of off notes, as compared to the off-notes perceived upon consumption of natural spilanthol (e.g. spilanthol obtained from jambu oleoresin). Methods of increasing salivation and/or providing a tingling sensation upon consuming an orally consumable product that include adding to the product a synthetic spilanthol flavor composition are also provided.
    Type: Application
    Filed: July 17, 2009
    Publication date: July 22, 2010
    Applicant: Takasago International Corporation
    Inventors: Louis Lombardo, Michael E. Lankin, Kenya Ishida, Shigeru Tanaka, Hideo Ujihara, Kenji Yagi, Jennifer B. Mei, Carter B. Green, Amrit S. Mankoo
  • Publication number: 20100184864
    Abstract: Disclosed are: a material which contains a lipophilic component having a pungent taste or flavor such as a spicy component (e.g., a capsaicin) and a bitter component (e.g., a turmeric extract), in which the pungent taste and/or flavor of the lipophilic component can be reduced effectively, and in which the separation among components contained therein is not caused; a method for producing the material; a composition such as a food, a beverage, a cosmetic and a medicine, which contains the material; and a liquid composition having such a form that the material is dispersed in water.
    Type: Application
    Filed: June 27, 2008
    Publication date: July 22, 2010
    Applicant: HOUSE FOODS CORPORATION
    Inventors: Tadashi Hamajima, Tomomi Yanagibayashi, Ryuji Arakawa, Morihiro Aoyagi, Masayoshi Kushi
  • Publication number: 20100172946
    Abstract: A matrix-type transdermal drug delivery system including capsaicin or a capsaicin derivative as an active component and used for treating neuropathy, pain, and inflammation and a preparation method thereof are provided. The matrix-type transdermal drug delivery system includes: a drug protecting layer; a matrix layer formed on the drug protecting layer and including 0.1-25 wt % of capsaicin or a capsaicin derivative, 40-95 wt % of an adhesive including a water-insoluble acrylic polymer, 1-30 wt % of an alcohol having a molecular weight of 600 Daltons or less, 0.1-20 wt % of a nonionic surfactant, and 0.1-20 wt % of a solubilizing agent including a hydrophilic polymer; and a release liner formed on the matrix layer, and is used for treating neuropathy, pain, or inflammation.
    Type: Application
    Filed: June 5, 2008
    Publication date: July 8, 2010
    Applicant: SAMYANG CORPORATION
    Inventors: Jin-Deok Song, Dong-Won Kim
  • Publication number: 20100160261
    Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.
    Type: Application
    Filed: August 4, 2009
    Publication date: June 24, 2010
    Inventor: Samuel FORTIN
  • Publication number: 20100152272
    Abstract: Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester moiety), —COCH2CH2CH2CH2CH2O— (caprolactone ester moiety), —CO(CH2)mO—, where m is 2-4 or 6-24 and —COCH2O(CH2CH2O)n— where n is between 2-24; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
    Type: Application
    Filed: February 17, 2010
    Publication date: June 17, 2010
    Applicant: BEZWADA BIOMEDICAL, LLC
    Inventor: Rao S. Bezwada
  • Publication number: 20100143478
    Abstract: The invention provides methods of inhibiting inflammation and/or the complement cascade and/or the kinin cascade in a human or non-human animal patient, particularly in a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The affected location of the patient is contacted with a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule.
    Type: Application
    Filed: January 17, 2008
    Publication date: June 10, 2010
    Inventor: Hugh Semple Munro
  • Publication number: 20100137251
    Abstract: The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of cannabimimetic agents and combinations thereof.
    Type: Application
    Filed: December 4, 2009
    Publication date: June 3, 2010
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: David W. Carley, Miodrag Radulovacki
  • Publication number: 20100120780
    Abstract: Provided are methods and compositions for the treatment of a sexual dysfunction such as premature ejaculation. In certain embodiments, a NMDA antagonist (e.g., dextromethorphan) is administered to a subject in combination with tramadol or a tramadol derivative to treat premature ejaculation. In certain embodiments, a capsaicinoid (e.g., capsaicin) and/or a phosphodiesterase type V inhibitor (e.g., sildenafil citrate) are further administered to the subject. Pharmaceutical preparations such as tablets and capsules are provided.
    Type: Application
    Filed: April 18, 2008
    Publication date: May 13, 2010
    Inventor: Chandra Ulagaraj Singh
  • Patent number: 7705039
    Abstract: A method of ameliorating a sleep-related breathing disorder via administration of at least one cannabimimetic agent, such as oleamide or ?9THC, to an individual in need of treatment.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: April 27, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David W. Carley, Miodrag Radulovacki
  • Publication number: 20100099772
    Abstract: The invention features a method for inhibiting one or more voltage-gated ion channels in a cell by contacting the cell with (i) a first compound that activates a channel-forming receptor that is present on nociceptors and/or pruriceptors; and (ii) a second compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels, wherein the second compound is capable of entering nociceptors or pruriceptors through the channel-forming receptor when the receptor is activated. The invention also features a quarternary amine derivative or other permanently or transiently charged derivative of a compound that inhibits one or more voltage-gated ion channels when applied to the internal face of the channels but does not substantially inhibit said channels when applied to the external face of the channels.
    Type: Application
    Filed: November 19, 2007
    Publication date: April 22, 2010
    Inventors: Bruce P. Bean, Clifford J. Woolf